6月16日 - ** Sarepta Therapeutics SRPT.O股价盘前暴跌28%，至26.11美元，此前 (link)，该公司披露了基因疗法治疗一种罕见肌肉萎缩症的第二例死亡病例。
** 如果跌势持续，Sarepta 将损失三分之一的市值
** 第一例死亡病例于 3 月份报告
** 肝损伤是 Elevidys 和其他使用腺相关病毒载体注入修饰基因的基因疗法的一个已知风险
** 该公司称已暂停向无法行走的患者运送治疗药物，并已通知全球卫生机构和美国食品及药物管理局
** 截至上次收盘，SRPT 累计下跌 70.2
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.